Baseline characteristics of patients and their impact on RFS
| Parameter . | N (%)/median (range) . | Impact on RFS (P) . |
|---|---|---|
| Age, y | ||
| < 10 | 18 (11.9) | |
| 11-15 | 15 (9.9) | NS |
| 16-55 | 111 (73.5) | |
| > 55 | 7 (4.6) | |
| Sex: male | 79 (52.3) | NS |
| Hemoglobin, × 10 g/Lt | 8.6 (2.1-16) | NS |
| WBC | ||
| < 5 × 109/Lt | 78 (51.7) | NS |
| ≥ 5 × 109/Lt | 73 (48.3) | |
| < 10 × 109/Lt | 98 (64.9) | NS |
| ≥ 10 × 109/Lt | 53 (35.1) | |
| Platelets | NS | |
| ≤ 20 × 109/Lt | 86 (57.0) | |
| > 20 × 109/Lt | 65 (43.0) | |
| Good-risk group* | 41 (27.2) | NS |
| High-risk group | 110 (72.8) | |
| RT-PCR | ||
| bcr1 | 92 (61.3) | |
| bcr2 | 9 (6.0) | NS |
| bcr3 | 49 (32.7) | |
| Lactate dehydrogenase, IU/Lt | 527 (75-2700) | NS |
| Serum creatinine, mg/100 mL | 0.8 (0.1-1.6) | NS |
| Additional CTG finding | ||
| Yes | 42 (31.1) | .001 |
| No | 93 (68.9) | |
| FLT3 mutation (ITD/TKD) | ||
| Yes | 36 (26.5) | NS |
| No | 100 (73.5) |
| Parameter . | N (%)/median (range) . | Impact on RFS (P) . |
|---|---|---|
| Age, y | ||
| < 10 | 18 (11.9) | |
| 11-15 | 15 (9.9) | NS |
| 16-55 | 111 (73.5) | |
| > 55 | 7 (4.6) | |
| Sex: male | 79 (52.3) | NS |
| Hemoglobin, × 10 g/Lt | 8.6 (2.1-16) | NS |
| WBC | ||
| < 5 × 109/Lt | 78 (51.7) | NS |
| ≥ 5 × 109/Lt | 73 (48.3) | |
| < 10 × 109/Lt | 98 (64.9) | NS |
| ≥ 10 × 109/Lt | 53 (35.1) | |
| Platelets | NS | |
| ≤ 20 × 109/Lt | 86 (57.0) | |
| > 20 × 109/Lt | 65 (43.0) | |
| Good-risk group* | 41 (27.2) | NS |
| High-risk group | 110 (72.8) | |
| RT-PCR | ||
| bcr1 | 92 (61.3) | |
| bcr2 | 9 (6.0) | NS |
| bcr3 | 49 (32.7) | |
| Lactate dehydrogenase, IU/Lt | 527 (75-2700) | NS |
| Serum creatinine, mg/100 mL | 0.8 (0.1-1.6) | NS |
| Additional CTG finding | ||
| Yes | 42 (31.1) | .001 |
| No | 93 (68.9) | |
| FLT3 mutation (ITD/TKD) | ||
| Yes | 36 (26.5) | NS |
| No | 100 (73.5) |
NS indicates not significant.
Defined as WBC < 5 × 109/Lt and platelets > 20 × 109/Lt.